FDA Approvals in Oncology: January-March 2026
In the first quarter of 2026, the FDA issued nine approvals in oncology, including treatments for blood cancers, pancreatic...
Author:
Cancer Research Catalyst Staff
In the first quarter of 2026, the FDA issued nine approvals in oncology, including treatments for blood cancers, pancreatic...
In March, AACR's journals editors highlighted studies on the development of pediatric leukemia, the use of low-dose tamoxifen, and...
In February, the editors of AACR's journals highlighted studies on the FDA’s accelerated approval pathway, how metabolism impacts prostate...
What does a naked mole rat, a nuclear exporter that “moonlights” as a chromatin regulator, and the combined power...
In the last quarter of 2025, the FDA announced 20 approvals in oncology, including treatments for lung cancer, multiple...
The countdown to the new year is nearly upon us, but no need to count down to the last...
A year-end review of some of the new cancer treatments, exciting breakthroughs, and insights into cancer's development that emerged...
In November, the AACR’s journal editors highlighted studies on sucralose limiting immunotherapy, benefits of caloric restriction, and more.
Shawn Lee, MD, PhD, an AACR-St. Baldrick’s Foundation Grantee, is working to personalize therapies for children with acute lymphoblastic...
In October 2025, AACR's journals editors highlighted studies on the anticancer function of an Alzheimer’s-related protein, small-molecule-drug conjugates, and...